Rabies - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Rabies - Pipeline Review, H1 2016', provides an overview of the Rabies pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rabies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rabies and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Rabies - The report reviews pipeline therapeutics for Rabies by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Rabies therapeutics and enlists all their major and minor projects - The report assesses Rabies therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Rabies Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Rabies - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Rabies Overview 9 Therapeutics Development 10 Pipeline Products for Rabies - Overview 10 Pipeline Products for Rabies - Comparative Analysis 11 Rabies - Therapeutics under Development by Companies 12 Rabies - Therapeutics under Investigation by Universities/Institutes 14 Rabies - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Rabies - Products under Development by Companies 18 Rabies - Products under Investigation by Universities/Institutes 19 Rabies - Companies Involved in Therapeutics Development 20 Beijing Minhai Biotechnology Co., Ltd 20 Celltrion, Inc. 21 CureVac GmbH 22 Humabs BioMed SA 23 Kaketsuken K.K. 24 Kamada Ltd. 25 Medicago Inc. 26 Molecular Targeting Technologies, Inc. 27 NanoViricides, Inc. 28 Novavax, Inc. 29 PaxVax, Inc. 30 Prosetta Biosciences, Inc. 31 Sanofi Pasteur SA 32 Serum Institute of India Limited 33 Sinovac Biotech Ltd. 34 Trellis Bioscience, Inc. 35 VBI Vaccines Inc. 36 Zydus Cadila Healthcare Limited 37 Rabies - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Combination Products 39 Assessment by Target 40 Assessment by Mechanism of Action 42 Assessment by Route of Administration 44 Assessment by Molecule Type 46 Drug Profiles 48 (Ebola [Zaire] + rabies) (bivalent) vaccine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 CTP-19 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 CV-8102 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 KD-357 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Monoclonal Antibodies for Rabies - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Monoclonal Antibodies to Inhibit Glycoprotein for Rabies - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Monoclonal Antibody for Rabies - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 nadorameran - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 PAV-866 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 RabiCide-I - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 rabies (virus like particle) vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 rabies [strain Wistar PM/WI 38-1503-3M] vaccine - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 rabies immune globulin (human) - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 rabies vaccine - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 rabies vaccine - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 rabies vaccine - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 rabies vaccine - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 rabies vaccine - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 rabies vaccine - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 rabies vaccine - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 rabies vaccine - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Rabimabs - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 SII RMab - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 SO-57 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 SOJB - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 SYN-023 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Rabies - Recent Pipeline Updates 77 Rabies - Dormant Projects 80 Rabies - Product Development Milestones 81 Featured News & Press Releases 81 Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant 81 Dec 23, 2015: Kamada's Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment 82 Mar 23, 2015: Yisheng Biopharma develops new therapeutic vaccine for rabies 83 Mar 04, 2014: Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies 84 Aug 28, 2009: Rabies Vaccine Supply Update: IMOVAX Rabies Vaccine Availability 84 Jul 15, 2008: Kamada Gains Approval of KamRAB in Israel 85 Oct 23, 2007: Kamada Awarded Another Contract To Deliver Its KamRAB Anti-rabies Vaccination To Latin America 85 May 01, 2007: Kamada Obtains FDA Approval to Commence Phase II and III Clinical Trials For Its KamRAB Anti-rabies Passive Immunization Product 86 Sep 18, 2003: Molecular Targeting Technologies, Inc. Forms Partnership With North China Pharmaceutical Company 86 Appendix 87 Methodology 87 Coverage 87 Secondary Research 87 Primary Research 87 Expert Panel Validation 87 Contact Us 87 Disclaimer 88
List of Tables
Number of Products under Development for Rabies, H1 2016 10 Number of Products under Development for Rabies - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Investigation by Universities/Institutes, H1 2016 19 Rabies - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 20 Rabies - Pipeline by Celltrion, Inc., H1 2016 21 Rabies - Pipeline by CureVac GmbH, H1 2016 22 Rabies - Pipeline by Humabs BioMed SA, H1 2016 23 Rabies - Pipeline by Kaketsuken K.K., H1 2016 24 Rabies - Pipeline by Kamada Ltd., H1 2016 25 Rabies - Pipeline by Medicago Inc., H1 2016 26 Rabies - Pipeline by Molecular Targeting Technologies, Inc., H1 2016 27 Rabies - Pipeline by NanoViricides, Inc., H1 2016 28 Rabies - Pipeline by Novavax, Inc., H1 2016 29 Rabies - Pipeline by PaxVax, Inc., H1 2016 30 Rabies - Pipeline by Prosetta Biosciences, Inc., H1 2016 31 Rabies - Pipeline by Sanofi Pasteur SA, H1 2016 32 Rabies - Pipeline by Serum Institute of India Limited, H1 2016 33 Rabies - Pipeline by Sinovac Biotech Ltd., H1 2016 34 Rabies - Pipeline by Trellis Bioscience, Inc., H1 2016 35 Rabies - Pipeline by VBI Vaccines Inc., H1 2016 36 Rabies - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 37 Assessment by Monotherapy Products, H1 2016 38 Assessment by Combination Products, H1 2016 39 Number of Products by Stage and Target, H1 2016 41 Number of Products by Stage and Mechanism of Action, H1 2016 43 Number of Products by Stage and Route of Administration, H1 2016 45 Number of Products by Stage and Molecule Type, H1 2016 47 Rabies Therapeutics - Recent Pipeline Updates, H1 2016 77 Rabies - Dormant Projects, H1 2016 80
List of Figures
Number of Products under Development for Rabies, H1 2016 10 Number of Products under Development for Rabies - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Products, H1 2016 17 Assessment by Monotherapy Products, H1 2016 38 Number of Products by Targets, H1 2016 40 Number of Products by Stage and Targets, H1 2016 40 Number of Products by Mechanism of Actions, H1 2016 42 Number of Products by Stage and Mechanism of Actions, H1 2016 42 Number of Products by Routes of Administration, H1 2016 44 Number of Products by Stage and Routes of Administration, H1 2016 44 Number of Products by Molecule Types, H1 2016 46 Number of Products by Stage and Molecule Types, H1 2016 46
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected toRead More...
Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecastRead More...
Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growtRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.